Posted inBusiness Insights
Eli Lilly Raises 2026 Outlook After Strong Q2 Earnings and Surge in Zepbound Sales
Eli Lilly upgraded its 2026 financial outlook following a surge in Zepbound and Mounjaro sales, easily topping quarterly Wall Street estimates.
